Clinical Trial Navigator

Model: meta-llama/llama-3.3-70b-instruct
Status: Completed
Cost: $0.046
Tokens: 155,190
Started: 2026-01-05 14:35

Expansion Plan for Clinical Trial Navigator

Expansion Readiness

Prerequisites for Expansion Status Target Notes
Product-Market Fit in core market ✓ Achieved D30 retention >35% Must achieve before expansion
Unit economics proven ✓ Proven LTV:CAC >3:1 Sustainable in core market
Operational processes established ✓ Established Scalable systems Can be replicated
Team capacity ✓ Available Dedicated resources Need bandwidth for expansion
Capital/runway ✓ Secured 12+ months Fund expansion activities

Geographic Expansion

Phase 1: English-Speaking Countries

  • UK
  • Canada
  • Australia

Phase 2: European Countries

  • Germany
  • France
  • Netherlands

Market Expansion

Expand to new patient segments, including those with rare diseases and chronic conditions.

  • Rare disease communities
  • Chronic condition support groups
  • Online health forums

Business Model Expansion

Explore new revenue streams through partnerships with pharmaceutical companies and research institutions.

  • Pharmaceutical company partnerships
  • Research institution collaborations
  • Data analytics services

12-Month Expansion Roadmap

  1. Months 1-3: Establish partnerships with patient advocacy groups
  2. Months 4-6: Launch Phase 1 geographic expansion
  3. Months 7-9: Develop and launch new features for market expansion
  4. Months 10-12: Analyze results and plan for future expansion

Revenue Projections

Timeframe USA UK/CA/AU EU Total
Month 6 $100,000 $20,000 $0 $120,000
Month 12 $200,000 $50,000 $20,000 $270,000

Expansion Risks and Mitigations

Risk Mitigation
Regulatory challenges Establish relationships with regulatory bodies
Market competition Differentiate through patient-centric approach
Technical issues Invest in robust infrastructure and maintenance

Expansion Success Metrics

  • Monthly active users
  • Trial matches per user
  • Click-through to trial coordinator contact
  • Premium conversion rate
  • Patient enrollment attribution (B2B)